Literature DB >> 24698666

Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis.

Chiara Quarneti1, Paolo Muratori, Claudine Lalanne, Angela Fabbri, Rita Menichella, Alessandro Granito, Chiara Masi, Marco Lenzi, Fabio Cassani, Georgios Pappas, Luigi Muratori.   

Abstract

BACKGROUND & AIMS: In recent years, primary biliary cirrhosis is mostly diagnosed in patients who are asymptomatic; however, a proportion of cases still present with typical complaints such as fatigue and/or pruritus. We compared biochemical, histological and immunological features of patients with or without fatigue and/or pruritus at onset to see whether the different clinical presentation may eventually impact on disease progression.
METHODS: We analysed the Bologna cohort of 216 patients with primary biliary cirrhosis referred to our Centre between 1997 and 2007, according to symptomatic (fatigue and/or pruritus) or asymptomatic presentation. Clinical, biochemical, histological and immunological feature at diagnosis, response to ursodeoxycholic acid and progression of the disorder were compared after a mean follow-up of 81 ± 75 months.
RESULTS: At diagnosis, symptomatic patients were significantly more often women (98.6% vs. 87.2%, P = 0.004), younger (mean age 49 ± 12 vs. 55 ± 12 years, P = 0.003) and with more pronounced biochemical activity, as indicated by higher alkaline phosphatase (mean 2.93 ± 2 vs. 2.12, P = 0.002) and aminotransferase (mean 1.92 ± 1 vs. 1.47 ± 1.27, P = 0.014) levels, whereas histological stage and autoantibody profile were similar. Symptomatic patients were less likely to respond to ursodeoxycholic acid therapy (63% vs. 81%, P = 0.006) and developed more often cirrhosis and its complications (31% vs. 13%, P = 0.004).
CONCLUSIONS: Fatigue and/or pruritus at onset identify a subset of patients with primary biliary cirrhosis who preferentially are women, younger, with a particularly active disease, less responsive to ursodeoxycholic acid treatment, and more inclined to evolve to cirrhosis and its complications.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  antimitochondrial antibodies; biliary; cirrhosis; symptomatic; therapy

Mesh:

Substances:

Year:  2014        PMID: 24698666     DOI: 10.1111/liv.12560

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  16 in total

1.  Hepatobiliary Quiz Answers-17 (2016).

Authors:  Sahaj Rathi; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2016-05-04

Review 2.  [Modern treatment of primary biliary cholangitis].

Authors:  C P Strassburg
Journal:  Internist (Berl)       Date:  2018-01       Impact factor: 0.743

Review 3.  New therapies for primary biliary cirrhosis.

Authors:  Annarosa Floreani; Irene Franceschet; Lisa Perini; Nora Cazzagon; M Eric Gershwin; Christopher L Bowlus
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

Review 4.  Recent advances in the development of farnesoid X receptor agonists.

Authors:  Ahmad H Ali; Elizabeth J Carey; Keith D Lindor
Journal:  Ann Transl Med       Date:  2015-01

5.  The latest research trends in primary biliary cholangitis: a bibliometric analysis.

Authors:  Yu Zhao; Zhenjie Yin; Huang Du; Kangming Huang; Fajing Zhang; Hongbin Chen
Journal:  Clin Exp Med       Date:  2022-04-07       Impact factor: 3.984

Review 6.  Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy.

Authors:  Treta Purohit; Mitchell S Cappell
Journal:  World J Hepatol       Date:  2015-05-08

Review 7.  Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis: a Review Featuring a Women's Health Perspective.

Authors:  Renée M Marchioni Beery; Haleh Vaziri; Faripour Forouhar
Journal:  J Clin Transl Hepatol       Date:  2014-12-15

8.  Polymorphisms of IL12RB2 May Affect the Natural History of Primary Biliary Cholangitis: A Single Centre Study.

Authors:  Urszula Wasik; Ewa Wunsch; Gary L Norman; Eirini I Rigopoulou; Dimitrios P Bogdanos; Piotr Milkiewicz; Małgorzata Milkiewicz
Journal:  J Immunol Res       Date:  2017-02-19       Impact factor: 4.818

Review 9.  Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists.

Authors:  Palak J Trivedi; Christophe Corpechot; Albert Pares; Gideon M Hirschfield
Journal:  Hepatology       Date:  2015-11-26       Impact factor: 17.425

Review 10.  Recent advances in the diagnosis and treatment of primary biliary cholangitis.

Authors:  Ying-Qiu Huang
Journal:  World J Hepatol       Date:  2016-11-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.